The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues

被引：3
|
作者：
Wang, Yimeng [1 ]
Wang, Yao [1 ]
Yu, Jinming [2 ,3 ,4 ]
Meng, Xiangjiao [2 ,3 ,4 ]
机构：
[1] Shandong First Med Univ, Dept Radiat Oncol, Shandong Canc Hosp, Jinan, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Shandong, Peoples R China
[3] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China
[4] Chinese Acad Med Sci, Res Unit Radiat Oncol, Jinan, Shandong, Peoples R China
来源：
CANCER LETTERS | 2022年 / 551卷
基金：
中国国家自然科学基金;
关键词：
Locally advanced non-small-cell lung cancer (LA-NSCLC); Immune-checkpoint inhibitors (ICIs); Combination therapies; PHASE-III TRIAL; ELECTIVE NODAL IRRADIATION; CONCURRENT CHEMORADIATION; RADIATION-THERAPY; REAL-WORLD; OPEN-LABEL; PROGRESSION-FREE; ADVERSE EVENTS; STAGE IIIA; DURVALUMAB;
D O I：
10.1016/j.canlet.2022.215947
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment efficacy for patients with unresectable, locally advanced non-small-cell lung cancer (LA-NSCLC) stagnated for a long time until the advent of immunotherapy. Immune checkpoint inhibitors, particularly programmed cell death protein 1/programmed death-ligand 1 inhibitors, have thrived, reshaping the treatment landscape for patients with lung cancer. Based on the results of the PACIFIC trial, concurrent chemoradiotherapy followed by durvalumab has become the standard of care for patients with unresectable LA-NSCLC; however, numerous issues are yet to be resolved. Currently, several clinical trials are exploring an optimal treatment paradigm, and we have summarized them for comparison to eliminate barriers. In addition, we discuss better predictive biomarkers, therapeutic options for specific populations, and other challenges to identify directions for future research design.
引用
收藏
页数：11
相关论文
共 50 条
  • [1] Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Sonam Puri
    Andreas Saltos
    Bradford Perez
    Xiuning Le
    Jhanelle E. Gray
    [J]. Current Oncology Reports, 2020, 22
  • [2] Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Puri, Sonam
    Saltos, Andreas
    Perez, Bradford
    Le, Xiuning
    Gray, Jhanelle E.
    [J]. CURRENT ONCOLOGY REPORTS, 2020, 22 (04)
  • [3] Locally advanced, unresectable non-small cell lung cancer - New treatment strategies
    Johnson, DH
    [J]. CHEST, 2000, 117 (04) : 123S - 126S
  • [4] Chemoradiotherapy in Locally Advanced, Unresectable Non-Small Cell Lung Cancer
    Mitchell, Lauren R.
    Albert, Jeffrey M.
    Lu, Bo
    [J]. REVIEWS ON RECENT CLINICAL TRIALS, 2009, 4 (02) : 110 - 121
  • [5] Novel approaches to locally advanced unresectable non-small cell lung cancer
    Stevens, CW
    Lee, JS
    Cox, J
    Komaki, R
    [J]. RADIOTHERAPY AND ONCOLOGY, 2000, 55 (01) : 11 - 18
  • [6] Treatment of Locally Advanced Non-Small Cell Lung Cancer
    Tam, Kit
    Daly, Megan
    Kelly, Karen
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (01) : 45 - +
  • [7] Management of Oncogene Driven Locally Advanced Unresectable Non-small Cell Lung Cancer
    Loh, Jerold
    Low, Jia Li
    Sachdeva, Manavi
    Low, Peter Q. J.
    Wong, Rachel Su Jen
    Huang, Yiqing
    Chia, Puey Ling
    Soo, Ross A.
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (09) : 913 - 926
  • [8] SIGNIFICANCE OF CONSOLIDATION CHEMOTHERAPY IN UNRESECTABLE, LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER
    Akamatsu, Hiroaki
    [J]. ANNALS OF ONCOLOGY, 2014, 25
  • [9] Is there a standard treatment for locally advanced non-small cell lung cancer?
    Buccheri, G
    [J]. CHEST, 1996, 109 (04) : 864 - 866
  • [10] Treatment Outcome of Locally Advanced Non-small Cell Lung Cancer
    Lee, Heui Kwan
    Kwon, Hyoung-Cheol
    Lee, Sun Young
    Kim, Jung Soo
    [J]. RADIATION ONCOLOGY JOURNAL, 2006, 24 (04): : 237 - 242
12345